ISSN |
1007-9327 (print) and 2219-2840 (online) |
Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
|
Copyright |
© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
|
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Gastroenterology & Hepatology |
Manuscript Type |
Observational Study |
Article Title |
Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus
|
Manuscript Source |
Unsolicited Manuscript |
All Author List |
Neal Patel, Kian Bichoupan, Lawrence Ku, Rachana Yalamanchili, Alyson Harty, Donald Gardenier, Michel Ng, David Motamed, Viktoriya Khaitova, Nancy Bach, Charissa Chang, Priya Grewal, Meena Bansal, Ritu Agarwal, Lawrence Liu, Gene Im, Jennifer Leong, Leona Kim-Schluger, Joseph Odin, Jawad Ahmad, Scott Friedman, Douglas Dieterich, Thomas Schiano, Ponni Perumalswami and Andrea Branch |
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
National Institutes of Health |
DA031095 |
National Institutes of Health |
DK090317 |
|
Corresponding Author |
Andrea Branch, PhD, Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, Icahn Medical Institute, 11th floor, Room 24, 1425 Madison Avenue, New York, NY 10029, United States. andrea.branch@mssm.edu |
Key Words |
Hepatitis C virus; Sofosbuvir; Ribavirin; Anemia; Hepatic decompensation; Serious adverse event; Liver transplant |
Core Tip |
Direct acting antivirals have changed the landscape of managing hepatitis C virus (HCV) infection, but there is limited data on the full safety profile of these drugs. We studied a group of liver transplant recipients with recurrent HCV who had hepatic decompensation and/or serious adverse events while on treatment with sofosbuvir-based regimens. We found that cases had lower pre-treatment hemoglobin, estimated glomerular filtration rate, and higher pre-treatment serum total bilirubin levels compared to controls. Anemia was the most common event and 62% of cases required blood transfusion. Similar to registration trials, sofosbuvir was generally well-tolerated, while ribavirin-induced anemia remains a challenge.
|
Publish Date |
2016-03-02 13:35 |
Citation |
Patel N, Bichoupan K, Ku L, Yalamanchili R, Harty A, Gardenier D, Ng M, Motamed D, Khaitova V, Bach N, Chang C, Grewal P, Bansal M, Agarwal R, Liu L, Im G, Leong J, Kim-Schluger L, Odin J, Ahmad J, Friedman S, Dieterich D, Schiano T, Perumalswami P, Branch A. Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus. World J Gastroenterol 2016; 22(9): 2844-2854 |
URL |
http://www.wjgnet.com/1007-9327/full/v22/i9/2844.htm |
DOI |
http://dx.doi.org/10.3748/wjg.v22.i9.2844 |